Table of Contents
ISRN Pharmaceutics
Volume 2012 (2012), Article ID 950162, 7 pages
http://dx.doi.org/10.5402/2012/950162
Research Article

Evaluation of an Innovative Over-the-Counter Treatment for Symptoms of Reflux Disease: Quick-Dissolving Alginate Granules

1Technostics Ltd., Daisy Building, 2nd Floor, Castle Hill Hospital, Cottingham, East Yorkshire HU16 5JQ, UK
2Global Professional Relations, Reckitt Benckiser Group plc, 103-105 Bath Road, Slough, Berkshire SL1 3UH, UK

Received 24 October 2012; Accepted 13 November 2012

Academic Editors: F. Fullas, Y. Murata, and G. Ragno

Copyright © 2012 Vicki Strugala et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Robinson, S. Rodriguez-Stanley, P. B. Miner, A. J. McGuire, K. Fung, and A. A. Ciociola, “Effects of antacid formulation on postprandial oesophageal acidity in patients with a history of episodic heartburn,” Alimentary Pharmacology and Therapeutics, vol. 16, no. 3, pp. 435–443, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. J. A. McGlashan, L. M. Johnstone, J. Sykes, V. Strugala, and P. W. Dettmar, “The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux,” European Archives of Oto-Rhino-Laryngology, vol. 266, no. 2, pp. 243–251, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Chatfield, “A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease,” Current Medical Research and Opinion, vol. 15, no. 3, pp. 152–159, 1999. View at Google Scholar · View at Scopus
  4. S. W. Lindow, P. Regnéll, J. Sykes, and S. Little, “An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy,” International Journal of Clinical Practice, vol. 57, no. 3, pp. 175–179, 2003. View at Google Scholar · View at Scopus
  5. V. Strugala, J. Bassin, V. S. Swales, S. W. Lindow, P. W. Dettmar, and E. C. M. Thomas, “Assessment of the safety and efficacy of a raft-forming alginate reflux suppressant for the treatment of heartburn during pregnancy,” ISRN Obstetrics & Gynecology, vol. 2012, Article ID 484870, 6 pages, 2012. View at Google Scholar
  6. K. Furu and B. Straume, “Use of antacids in a general population. The impact of health-related variables, lifestyle and sociodemographic characteristics,” Journal of Clinical Epidemiology, vol. 52, no. 6, pp. 509–516, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. R. P. Schneider and A. C. Roach, “An antacid tasting: the relative palatability of 19 liquid antacids,” Southern Medical Journal, vol. 69, no. 10, pp. 1312–1313, 1976. View at Google Scholar · View at Scopus
  8. M. E. Temple and M. C. Nahata, “Comparative palatability of 22 liquid antacids,” Alimentary Pharmacology and Therapeutics, vol. 14, no. 4, pp. 421–425, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. M. R. Jacyna, E. J. S. Boyd, and K. G. Wormsley, “Comparative study of four antacids,” Postgraduate Medical Journal, vol. 60, no. 707, pp. 592–596, 1984. View at Google Scholar · View at Scopus
  10. A. L. Blum, “Why do dyspeptic patients prefer one liquid antacid to another?” European Journal of Clinical Investigation, vol. 16, no. 6, pp. 515–518, 1986. View at Google Scholar · View at Scopus
  11. C. Marriott, “The effect of flavour on acceptability of antacid tablets,” Journal of Clinical and Hospital Pharmacy, vol. 8, no. 1, pp. 69–73, 1983. View at Google Scholar · View at Scopus
  12. N. Bahal-O'Mara, R. W. Force, and M. C. Nahata, “Palatability of 14 over-the-counter antacids,” American Pharmacy, vol. 34, no. 1, pp. 31–35, 1994. View at Google Scholar · View at Scopus
  13. F. C. Hampson, A. Farndale, V. Strugala, J. Sykes, I. G. Jolliffe, and P. W. Dettmar, “Alginate rafts and their characterisation,” International Journal of Pharmaceutics, vol. 294, no. 1-2, pp. 137–147, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. “BP: alginate raft-forming oral suspension,” in British Pharmacopoeia, vol. 3, The Stationary Office, London, UK, 2007.
  15. F. C. Hampson, I. G. Jolliffe, A. Bakhtyari et al., “Alginate-antacid combinations: raft formation and gastric retention studies,” Drug Development and Industrial Pharmacy, vol. 36, no. 5, pp. 614–623, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. N. M. Davies, S. J. Farr, I. W. Kellaway, G. Taylor, and M. Thomas, “A comparison of the gastric retention of alginate containing tablet formulations with and without the inclusion of excipient calcium ions,” International Journal of Pharmaceutics, vol. 105, no. 2, pp. 97–101, 1994. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Taylor, S. J. Warren, I. W. Kellaway, B. Patel, and S. L. Little, “Gastric residence of Gaviscon Advance and Liquid Gaviscon in healthy volunteers,” Journal of Pharmacy and Pharmacology, vol. 49, article 73, 1997. View at Google Scholar
  18. F. C. Hampson, I. G. Jolliffe, A. Bakhtyari et al., “Alginate-antacid combinations: raft formation and gastric retention studies,” Drug Development and Industrial Pharmacy, vol. 36, no. 5, pp. 614–623, 2010. View at Publisher · View at Google Scholar · View at Scopus